Medac Satellite Symposium at EULAR 2024
This content was funded by medac.
Learn more about the management of patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), and psoriatic arthritis (PsA) by using first-line medication, methotrexate (MTX), optimally. Experts in their respective fields share their knowledge to help you to improve patient care.
Topics covered include:
- Retrospective data on the optimised RA therapy initiation strategy regarding doses and application routes.
- Basic information on the use of MTX in RA treatment, including the subcutaneous route and data from recent publications.
- The multidisciplinary approach for management of JIA.
- The challenges of PsA diagnosis and therapy and how dermatological-rheumatological cooperation can be achieved to help improve patient care.
Video Chapters:
- Comparison of Subcutaneous versus Oral MTX for Initiating RA Therapy – 00:01:30 (Jérôme Avouac)
- Clinical Benefits of Subcutaneous Methotrexate in RA Therapy – 00:21:17 (Ulf Müller-Ladner)
- Improving Conventional Therapy in Patients with Juvenile Idiopathic Arthritis – 00:43:19 (Pavla Doležalová)
- Rheumatological-dermatological cooperation: Earlier Psoriatic Arthritis Diagnosis and Improved Therapy with Conventional Medications – 01:01:58 (Valentin Schäfer)
Speakers:
Ulf Müller-Ladner, Professor of Internal Medicine and Rheumatology, Justus-Liebig University, Giessen, Germany
Jérôme Avouac, Professor of Rheumatology, Université de Paris Cité, Service de Rheumatologie, Hôpital Cochin, AP-HP.CUP, Paris, France
Pavla Doležalová, Professor, Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czechia
Valentin Schäfer, Professor, Department of Rheumatology and Clinical Immunology, Clinic of Internal medicine III, University Hospital Bonn, Germany
